BioHarvest Sciences, Inc. · NASDAQ:BHST
BioHarvest Sciences — Investor Presentation (January 2022)
38 slides from BioHarvest Sciences's investor presentation, January 2022
Slide 1: Forward-looking information disclaimer
The following presentation contains future looking information based on management expectations. Viewers are cautioned that future looking information is subject to risks and uncertainties including the risk that the company will not achieve its production and sales targets as anticipated or that pr
Slide 2: Global Leader in Plant Cell Biology
GLOBAL LEADER IN PLANT CELL BIOLOGY CSE: BHSC OTC: CNVCF FRANKFURT: 8MV
Slide 3: Next Generation Science-Based Therapeutics
BY UNLOCKING THE SECRETS OF CELLULAR PLANT BIOLOGY, WE BRING THE WORLD NEXT GENERATION SCIENCE-BASED futuristic THERAPEUTICS WITH A STRONG IP PORTFOLIO ADDRESSING A CURRENT 500 BILLION DOLLAR MARKET
Slide 4: Human body needs metabolites; nature provides them inefficiently
THE HUMAN BODY NEEDS PRIMARY AND SECONDARY METABOLYTES TO Resveratrol FUNCTION EFFECTIVELY Cannabinoids BUT Alkaloids Flavonoids MOTHER NATURE PROVIDES THEM INEFFICIENTLY Gossypol Polyphenols INCONSISTENT UNCLEAN HIGH COST DAMAGES THE ENVIRONMENT
Slide 5: Industrial Scale Platform
OUR BIO-PLANT CELLICITATION TECHNOLOGY IS THE ONLY INDUSTRIAL SCALE 100% PLATFORM CONSISTENCY THAT BRINGS PLANT BASED THERAPEUTIC SOLUTIONS OUR WHICH: ASEPTIC FIVE LOW CLEANLINESS C’S COST • MAINTAIN THE ORIGINAL NATURAL COMPOUND STRUCTURE • ARE FULL SPECTRUM WITHOUT GROWING ANY PLANT UNIQUE COMPOSI
Slide 6: Biotech leader addressing a ±500 billion USD market
BIOTECH LEADER WITH PROVEN PLATFORM TECHNOLOGY THAT ADRESSES A CURRENT ±500 BILLION USD MARKET OPPORTUNITY $ TGF $ $ $ FFG $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ Nutraceuticals Cannabinoids Psychedelics Botanical drugs Protein Growth Factors TCM USD 275 BILLION USD 25 BILLION USD 5 BILLION USD 35 BIL
Slide 7: Our Bio-Plant CELLicitation Platform Technology
Our Bio-Plant CELLicitation Platform Technology Polyphenols Cannabinoids Psychedelics* TCM* Growth Factors* 1 WE TAKE THE 3 STORE THEM 5HARVEST PLANT ONCE IN CELL BANK 2ISOLATE THE CELLS WITH 4 BIO-CELLICIT KEY ACTIVE INGREDIENTS Future Platforms *
Slide 8: 21 Days vs. 2 Years in nature
Our Bio-Plant CELLicitation Platform Technology Polyphenols Cannabinoids Psychedelics* TCM* Growth Factors* 1 WE TAKE THE 3 STORE THEM 5 HARVEST PLANT ONCE IN CELL BANK 2ISOLATE THE CELLS WITH 4 BIO-CELLICIT KEY ACTIVE INGREDIENTS 21 Days vs. 2 Years in nature Future Platforms *
Slide 9: VINIA demonstrates the power of our technology
VINIA demonstrates the power of our technology when applied to key therapeutics. Heart health Supports heart health by Blood pressure improving blood flow and Supports blood pressure delivery of oxygen.* Increases already within normal range dilation of arteries and blood vessels.* Physical energy E
Slide 10: VINIA has already sold USD 1.5M in 2021
VINIA has already sold USD 1.5 M in 2021 with significant expected revenue to be derived from the polyphenol vertical VINIA® Historical Revenue Growth in USD by Quarter Olive Cells Pomegranate Cells 700,000 600,000 500,000 +55% 400,000 USD $ +33% 300,000 +19% 200,000 +394% 100,000 Benefits of Medite
Slide 11: Our Bio-Plant CELLicitation Platform Technology
Our Bio-Plant CELLicitation Platform Technology Polyphenols Cannabinoids Psychedelics* TCM* Growth Factors* 1 WE TAKE THE 3 STORE THEM 5 HARVEST PLANT ONCE IN CELL BANK 2ISOLATE THE CELLS WITH 4 BIO-CELLICIT KEY ACTIVE INGREDIENTS Future Platforms *
Slide 12: 13 cycles per year vs. 2-3 cycles per year
Our Bio-Plant CELLicitation Platform Technology Polyphenols Cannabinoids Psychedelics* TCM* Growth Factors* 1 WE TAKE THE 3 STORE THEM 5 HARVEST PLANT ONCE IN CELL BANK 2ISOLATE THE CELLS WITH 4 BIO-CELLICIT KEY ACTIVE INGREDIENTS 13 Cycles per year VS. 2-3 Cycles per year Future Platforms *
Slide 13: Nature Bio-Plant CELLicitation
NATURE BIO-PLANT CELLICITATION WITHOUT HAVING TO GROW THE PLANT
Slide 14: Nature Bio-Plant CELLicitation
NATURE BIO-PLANT CELLICITATION WITHOUT HAVING TO GROW THE PLANT
Slide 15: Nature Bio-Plant CELLicitation
NATURE BIO-PLANT CELLICITATION WITHOUT HAVING TO GROW THE PLANT
Slide 16: Nature Bio-Plant CELLicitation
NATURE BIO-PLANT CELLICITATION WITHOUT HAVING TO GROW THE PLANT
Slide 17: Our platform mirrors and enhances nature via CELLicitation
Our platform mirrors and enhances nature via CELLicitation Red Grapes Cannabis Increase Piceid Resveratrol concentration Increase Trichome Density 100x Versus in a regular Grape 100-200x Versus in a regular Plant
Slide 18: Plant Based Therapeutics Comparative Data
Plant Based Therapeutics Comparative Data Conventional Farming+ extraction Biosynthesis Land use efficiency High Low High Production cost ($/kg) Low High Unknown Capex Low High Medium Production cycle times Low High Semi/Continuous Purity High Low High Consistency High Low High Full spectrum Composi
Slide 19: Superior scalability and ROI
Bio-Plant CELLicitation has Superior SCALABILITY and ROI $3-4M CAPEX + 1200 SQUARE = 20 METRIC TONS > $ 40M METERS OF PER YEAR OF IN POTENTIAL LAND ACTIVE PLANT REVENUE PER BASED YEAR COMPOUNDS
Slide 20: Sustainability is at the core of everything we do
Sustainability is at the 98% CORE of everything we do First Biotech company engaged in the production of Cannabis biomass and cannabinoids to publish an ESG Sustainability Report OUR GROWING PROCESS FOR CANNABIS USES 98% less land 90% less space than traditional than indoor growing outdoor agricultu
Slide 21: Our Cannabis breakthrough achievements
Our Cannabis breakthrough achievements 2 YEAR HIGH GROWING MULTIPLE DEVELOPMENT OF DEVELOPMENT OF PERFORMING STRAINS IN MULTIPLE DRYING PROCESS MEASUREMENT RESERVOIR BIOREACTORS TECHNIQUES 100% CONSISTENCY ASEPTIC CLEANLINESS CLIMATE FRIENDLY CONTINUOUS OUR UNIQUE FIGURE: 1 FIGURE: 2 FIGURE: 3 FLOWE
Slide 22: Our unique Amalgamated Trichome Coral Structure
Our unique “Amalgamated Trichome Coral Structure” is a game changer in many critical areas UNIQUE COMPOSITION
Slide 23: Trichomes grown at a density never seen before
Our technology only grows trichomes at a density the world has never seen before 100 – 200 X
Slide 24: We have now grown kilograms
Our technology only grows trichomes at a density the world has never seen before We have now grown Kilograms
Slide 25: Slide 25
Slide 26: Monetizing our technology across multiple channels starting in 2022
This unique quality of cannabis enables us to monetize our technology across multiple channels, starting in 2022 Pharma Ingredients (API’s) Trichome BioMass for Major Players Food & Beverage Ingredient B2B MEDICINAL CANNABIS HEMP BASED CBD DIETARY SUPPLEMENT D2C For Illustration Purposes Only
Slide 27: 93% Trichomes by BioHarvest
With “93% Trichomes” by BIOHARVEST - a major strategic Cannabis ingredient Pharma Ingredients (API’s) Trichome BioMass for Major Players Food & Beverage Ingredient B2B MEDICINAL CANNABIS HEMP BASED CBD DIETARY SUPPLEMENT D2C For Illustration Purposes Only
Slide 28: Company Historical Milestones
Company Historical Milestones Induced Cannabis cells to grow and successfully produced Cannabis Completed 20 Ton industrial-scale facility trichomes. for VINA® (in Israel) Launched successfully VINIA® in the US via Stably grew Cannabis cells in suspension, D2C channel. and cannabinoid molecules with
Slide 29: Led by a high-performance experienced management team
Led by a high-performance experienced management team Ilan Sobel DR. Yochi Hagay DR. Malkit Azachi Michal Sapir CEO CTO VP R&D VP Regulation Affairs Justin Meiklem Alan Rootenberg Kobi Rosenzweig Jarred Turner Head of IR CFO VP Operations VP of E-Commerce
Slide 30: Supported by a team of industry leaders
Supported by a team of industry leaders MEDICAL ADVISORY BOARD EITAN EITAN POPPER STEVEN LEHRER DR RHONA APPLEBAUM DR. DENNIS GOODMAN CANNABIS PIONEER BIOTECH REGULATORY AND SCIENTIFIC AFFAIRS CARDIOLOGIST SCOTT MCCUNE COL CHRIS HADFIELD ADV ROBERTO CHAIT DR DAVID BRADY CONSUMER MARKETING SPACE AND
Slide 31: Best in Class Biotech Capabilities serving Multiple Verticals
BUILT Best in Class BIOTECH Capabilities serving Multiple Verticals R&D REGULATION CLINICAL RESEARCH D2C SALES END TO END THE BRAIN MANUFACTURING COMMERCIAL BUSINESS MACHINE DEVELOPMENT/B2B SALES TECHNOLOGY PROCESSES
Slide 32: Best in Class Biotech Capabilities: R&D and Clinical Research
BUILT Best in Class BIOTECH Capabilities serving Multiple Verticals R&D CLINICAL RESEARCH $45M 14 3 INVESTED PATENTS CLINICAL THE BRAIN TRIALS 8 3 SCIENTIFIC PATENTS STUDIES PENDING
Slide 33: Best in Class Biotech Capabilities: Manufacturing
BUILT Best in Class BIOTECH Capabilities across Multiple Verticals 2 TON 20+ TONS END TO END PER YEAR PILOT PER YEAR INDUSTRIAL THE BRAIN MANUFACTURING PLANT (CANNABIS) MANUFACTURING FACILITY Patented Custom Custom BIO MEASUREMENT DRYING TECHNOLOGY REACTORS TECHNIQUES TECHNIQUES PROCESSES
Slide 34: High performing commercial machine
High performing commercial machine driving major results REGULATION D2C SALES BUSINESS DEVELOPMENT/B2B SALES COMMERCIAL MACHINE Produced according to FDA Guidelines
Slide 35: Take the Power of our Technology to New Frontiers
Take the Power of our Technology to New Frontiers Produce antioxidant compounds that can 1 Produce primary metabolites such as premium proteins that are needed to provide 2 help reduce human cellular stress and required nutrition for humans to live in space. prevent damage caused by microgravity and
Slide 36: Relevant comparable Biotech Platform Companies
Relevant comparable Biotech Platform Companies Bringing to the World the Next We partner with Nature to ORGANISM ENGINEERING AT create the building blocks of SCALE, Making biology easier Generation Plant-Based tomorrow. We design, create, to engineer. We believe Science Driven Therapeutics and scale
Slide 37: Investment Highlights
Investment Highlights: Global leader in Plant Cell Biology Innovative and disruptive Biotech Platform Technology enabling multiple verticals with a TAM of >US$ 500B High scalability with low capex requirements ($3-4M) able to generate > $US 40 MM in Annual Revenue Strong IP platform with multiple pa
Slide 38: Global Leader in Plant Cell Biology
GLOBAL LEADER IN PLANT CELL BIOLOGY “Partnering sustainably with nature for the next generation of plant-based therapeutics without growing the plant” Ilan Sobel - CEO BioHarvest Sciences Inc info@bioharvest.com Ilan@bioharvest.com
BioHarvest Sciences — Investor Presentation (January 2022) on 6ix